iKang Healthcare Group, Inc. (“iKang” or the “Company”)
(Nasdaq:KANG), the largest provider in China’s fast growing private
preventive healthcare services market with a market share of 13.6%
in terms of revenue in calendar year 2014, today announced its
unaudited financial results for the first quarter ended June 30,
2016.
Fiscal First Quarter Ended June 30, 2016
Financial Highlights
- Net revenues were US$101.2 million, an increase of 17.3%
year-over-year (an increase of 23.5% on RMB basis) (1)
- Gross profit was US$44.7 million, an increase of 6.1%
year-over-year (an increase of 11.8% on RMB basis) (1)
- Net income attributable to the Company was US$2.1 million,
a decrease of 80.6% year-over-year (a decrease of 79.6% on RMB
basis) (1)
- Non-GAAP net income attributable to the
Company(2) was US$2.6 million, a decrease of 77.1%
year-over-year (a decrease of 75.9% on RMB basis)
(1)
- Basic and diluted income per ADS attributable to common
shareholders were US$0.03 and US$0.03, respectively,
as compared to US$0.16 and US$0.15, respectively, in the
fiscal first quarter of 2015
- Non-GAAP basic and diluted income per ADS(3) attributable
to common shareholders were US$0.04 and US$0.04,
respectively, as compared to US$0.16 and US$0.16,
respectively, in the fiscal first quarter of 2015
(1) RMB basis refers to the year on year
comparison made on local currency – Chinese Renminbi basis.(2)
Non-GAAP net income attributable to the Company is defined as net
income attributable to the Company excluding share-based
compensation expenses. For more information on these non-GAAP
financial measures, please see the section captioned under
“Non-GAAP Financial Measures” and the tables captioned
“Reconciliation of GAAP and Non-GAAP Results” set forth at the end
of this release.(3) Non-GAAP basic and diluted earnings per ADS is
defined as non-GAAP net income divided by the weighted average
number of basic and diluted ADS.
Mr. Lee Ligang Zhang, Chairman and Chief
Executive Officer of iKang, commented on the results. “iKang
recorded a solid performance in the fiscal first quarter of 2016,
with overall revenue growth of 23.5% year-over-year. This increase,
spread over a broader customer base, indicates a positive direction
for the Company to expand as we continue to execute our strategic
priorities of investing in sustainable, long term growth.”
“Over the past quarter, iKang has invested in a
number of market initiatives to expand our geographical coverage
and deepen market penetration in fast-growing tier two and three
cities. Compared to June 30, 2015, we have added 19 new medical
centers and expanded into seven new cities – Weihai, Weifang,
Xi’an, Wuhu, Guiyang, Ningbo and Foshan – bringing our network to
92 medical centers as of August 31, 2016. We have also invested in
new service offerings for our expanding network and remain focused
on investing in the renovation, upgrade and ramping up of our
acquired medical centers.”
Mr. Zhang concluded, “amid an economic slowdown,
the management remains fully committed to executing our dual
expansion strategy that aligns acquisitions and investments with a
self-built model to advance network expansion. iKang will continue
to leverage this initiative to capture the tremendous opportunities
prevalent in the fast-growing Chinese private preventative
healthcare services market while delivering profitable and
sustainable business growth.”
Fiscal First Quarter ended June 30, 2016 UNAUDITED
FINANCIAL RESULTS
Net RevenuesNet revenues for the fiscal
first quarter were US$101.2 million, representing a 17.3%
increase from US$86.3 million in the same period of the
last fiscal year. As of June 30, 2016, the number of
self-owned medical centers totaled 90 compared to 73 as
of June 30, 2015. In the quarter, the Company served
approximately a total of 1,264,600 customer visits under both
corporate and individual programs, representing an increase of
22.0% over the fiscal first quarter of 2015.
The table below sets forth a breakdown of net revenues:
(US$ million) |
1st Fiscal Quarter Ended June 30,
2016 |
1st Fiscal Quarter Ended June 30,
2015 |
YoY % Change |
Medical Examinations |
85.0 |
72.0 |
|
18.0 |
% |
Disease Screening |
7.3 |
5.5 |
|
32.4 |
% |
Dental Services |
1.3 |
1.5 |
|
-17.7 |
% |
Other Services |
7.6 |
7.3 |
|
6.3 |
% |
Total |
101.2 |
86.3 |
|
17.3 |
% |
Medical Examinations: Net revenues for the
quarter were US$85.0 million, representing an 18.0% increase
from US$72.0 million in the same period of the last
fiscal year, which was in line with the increase in the number of
visits.
Disease Screening: Net revenues for the
quarter were US$7.3 million, representing a 32.4% increase
from US$5.5 million in the same period of the last fiscal
year. Disease screening services refer to the additional services
requested by individuals under the basic corporate medical
examination programs as a result of individual needs.
Dental Services: Net revenues for the
quarter were US$1.3 million, representing a 17.7% decrease
from US$1.5 million in the same period of the last fiscal
year.
Other Services: Net revenues for the
quarter were US$7.6 million, representing a 6.3% increase
from US$7.3 million in the same period of the last fiscal
year.
Cost of RevenuesCost of
revenues for the quarter was US$56.5 million, representing a
28.0% increase from US$44.2 million in the same period of
the last fiscal year.
Gross Profit and Gross
MarginGross profit for the quarter was US$44.7
million, representing a 6.1% increase from US$42.1
million in the same period of the last fiscal year. Gross
margin for the quarter was 44.2%, as compared to 48.8% in the first
quarter of fiscal 2015. Gross margin was diluted mainly due to the
addition of newly acquired medical centers which have lower gross
margins, as they were still in their ramping up period.
Operating ExpensesTotal
operating expenses for the quarter were US$37.9 million,
representing a 36.7% increase from US$27.7 million in the
same period of the last fiscal year.
Selling and marketing expensesSelling and
marketing expenses for the quarter were US$18.3 million,
accounting for 18.1% of total net revenues as compared to 16.3% in
the same period of the last fiscal year. The increase was mainly in
personnel cost as a result of the sales and marketing team
expansion in both existing and new geographic areas.
General and administrative expensesGeneral and
administrative expenses for the quarter were US$18.7 million,
accounting for 18.5% of total net revenues as compared to 15.0% in
the same period of the last fiscal year. The increase was
mainly in payroll and rental costs which were associated with our
expansion into new geographic areas. The professional service
expenses relating to the “going private” process also contributed
the increases.
Research and development expensesResearch and
development expenses for the quarter were US$884,000,
accounting for 0.9% of total net revenues as compared to 0.8% in
the same period of the last fiscal year, which reflected our
increasing investment in information technology infrastructure and
mobile health app.
Income from OperationsIncome
from operations for the quarter was US$6.8 million,
representing a 52.6% decrease from US$14.4 million in the
same period of the last fiscal year. Excluding share-based
compensation expenses of US$484,000 for this quarter
and US$492,000 for the same quarter last year, non-GAAP
income from operations for the quarter was US$7.3
million as compared to US$14.9 million, which reflected a
decline of 50.9% as a result of diluted gross margin and an
increase in operating expenses.
Net
Income Net income
attributable to the Company for the quarter was US$2.1
million, representing a decrease of 80.6% from US$10.7
million for the same period in the last fiscal year.
Non-GAAP net income for the quarter
was US$2.6 million, representing a decrease of 77.1%
from US$11.2 million for the same period in fiscal
2015.
Basic and Diluted Earnings per
ADSBasic and diluted income per ADS attributable to common
shareholders were US$0.03 and US$0.03, respectively,
compared to basic and diluted income per ADS attributable to common
shareholders of US$0.16 and US$0.15, respectively,
in the same quarter of fiscal 2015.
Non-GAAP basic and diluted income per ADS
attributable to common shareholders
were US$0.04 and US$0.04, respectively, compared to
basic and diluted income per ADS attributable to common
shareholders of US$0.16 and US$0.16, respectively,
in the same quarter of fiscal 2015.
STATEMENT REGARDING UNAUDITED FINANCIAL
INFORMATION
The unaudited financial information set forth
above is subject to adjustments that may be identified when audit
work is performed on the Company’s year-end financial statements,
which could result in significant differences from this unaudited
financial information.
NON-GAAP FINANCIAL MEASURES
To supplement our consolidated financial
statements which are presented in accordance with U.S. GAAP, we
also use non-GAAP operating income, non-GAAP net income and
non-GAAP EBITDA as additional non-GAAP financial measures. We
present these non-GAAP financial measures because they are used by
our management to evaluate our operating performance. We also
believe that these non-GAAP financial measures provide useful
information to investors and others in understanding and evaluating
our consolidated results of operations in the same manner as our
management and in comparing financial results across accounting
periods and to those of our peer companies.
Reconciliation of non-GAAP operating income,
non-GAAP net income and non-GAAP EBITDA to the most directly
comparable financial measures calculated and presented in
accordance with U.S. GAAP is set forth at the end of this
release.
About iKang Healthcare Group,
Inc.
iKang Healthcare Group, Inc. is the largest
provider in China’s fast growing private preventive healthcare
services market, accounting for approximately 13.6% of market share
in terms of revenue in calendar year 2014.
Through iKang’s integrated service platform and
established nationwide network of medical centers and third-party
service provider facilities, the Company provides comprehensive and
high quality preventive healthcare solutions, including a wide
range of medical examinations services and value-added services
including disease screening and other services. iKang’s customers
are primarily corporate customers who contract with the Company to
provide medical examination services to their employees and
clients, and pay for these services at pre-negotiated prices. iKang
also directly markets its services to individual customers. In the
fiscal year ended March 31, 2016, the Company served a total of 4.6
million customer visits under both corporate and individual
programs.
As of August 31, 2016, iKang’s nationwide
network consisted of 92(1) self-owned medical centers covering 27
of the most affluent cities in China, namely Beijing, Shanghai,
Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou,
Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha,
Yantai, Yinchuan, Weihai, Weifang, Shenyang, Xi’an, Wuhu, Guiyang,
Ningbo and Foshan as well as Hong Kong. The Company has also
supplemented its self-owned medical center network by contracting
with approximately 400 third-party service provider facilities in
over 150 cities, which include select independent medical
examination centers and hospitals across all of China’s provinces,
creating a nationwide network that allows iKang to serve its
customers in markets where it does not have self-owned medical
centers.
(1) Among the 92 self-owned medical centers, two
medical centers are currently operated primarily by the minority
shareholders of these medical centers or their parent company.
Forward-looking Statements
This press release contains forward-looking
statements. These statements, including management quotes and
business outlook, are made under the “safe harbor” provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
”will,” "estimate," "project," "predict," "believe," "expect,"
"anticipate," "intend," "potential," "plan," "goal" and similar
statements. iKang may also make written or oral
forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Such statements involve certain risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in the forward-looking statements.
These forward-looking statements include, but are not limited to,
statements about: the Company’s goals and strategies; its future
business development, financial condition and results of
operations; its ability to retain and grow its customer base and
network of medical centers; the growth of, and trends in, the
markets for its services in China; the demand for and market
acceptance of its brand and services; competition in its industry
in China; relevant government policies and regulations relating to
the corporate structure, business and industry; fluctuations in
general economic and business conditions in China. Further
information regarding these and other risks is included in iKang’s
filing with the Securities and Exchange Commission. iKang
undertakes no duty to update any forward-looking statement as a
result of new information, future events or otherwise, except as
required under applicable law.
|
IKANG HEALTHCARE GROUP, INC. |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(In thousands of US dollars, except share data and per
share data) |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
As of |
|
As of |
|
|
|
March 31, |
|
June 30, |
|
|
|
2016 |
|
2016 |
|
ASSETS |
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
108,111 |
|
$ |
62,067 |
|
Restricted
cash |
|
|
31,836 |
|
|
27,847 |
|
Term
deposits |
|
|
12,202 |
|
|
- |
|
Accounts
receivable, net of allowance for doubtful accounts of $14,329 |
|
|
74,163 |
|
|
97,682 |
|
and $14,874
as of March 31, 2016 and June 30, 2016, respectively |
|
|
|
|
|
|
|
Inventories |
|
|
4,015 |
|
|
4,236 |
|
Deferred tax
assets-current |
|
|
8,064 |
|
|
8,218 |
|
Amount due
from a related party |
|
|
4,653 |
|
|
5,488 |
|
Prepaid
expenses and other current assets |
|
|
62,659 |
|
|
65,132 |
|
|
|
|
|
|
|
|
|
Total current assets |
|
$ |
305,703 |
|
$ |
270,670 |
|
|
|
|
|
|
|
|
|
Property and equipment,
net |
|
$ |
130,170 |
|
$ |
134,439 |
|
Acquired intangible
assets, net |
|
|
37,179 |
|
|
33,886 |
|
Goodwill |
|
|
108,839 |
|
|
110,656 |
|
Long-term investments |
|
|
200,108 |
|
|
194,565 |
|
Deferred tax
assets-non-current |
|
|
8,077 |
|
|
9,054 |
|
Rental deposit and other
non-current assets |
|
|
13,565 |
|
|
14,669 |
|
|
|
|
|
|
|
|
|
TOTAL ASSETS |
|
$ |
803,641 |
|
$ |
767,939 |
|
|
|
|
|
|
|
|
|
LIABILITIES, MEZZANINE
EQUITY AND EQUITY (DEFICIT) |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts
payable (including accounts payable of the consolidated VIEs |
|
|
|
|
|
|
|
without
recourse to iKang Healthcare Group, Inc. of $22,685 |
|
|
|
|
|
|
|
and $24,873
as of March 31, 2016 and June 30, 2016, respectively) |
|
$ |
28,135 |
|
$ |
30,467 |
|
Accrued
expenses and other current liabilities (including accrued
expenses |
|
|
|
|
|
|
|
and other
current liabilities of the consolidated VIEs without recourse |
|
|
|
|
|
|
|
to iKang
Healthcare Group, Inc. of $41,319 and $38,897 as of March 31,
2016 |
|
|
|
|
|
|
|
and June 30,
2016, respectively) |
|
|
47,404 |
|
|
47,797 |
|
Income tax
payable (including income tax payable of the consolidated VIEs |
|
|
|
|
|
|
|
without
recourse to iKang Healthcare Group, Inc. of $7,386 and |
|
|
|
|
|
|
|
$5,655 as of
March 31, 2016 and June 30, 2016, respectively) |
|
|
8,216 |
|
|
6,932 |
|
Deferred
revenues (including deferred revenues of the consolidated VIEs |
|
|
|
|
|
|
|
without
recourse to iKang Healthcare Group, Inc. of $52,210 and |
|
|
|
|
|
|
|
$53,169 as
of March 31, 2016 and June 30, 2016, respectively) |
|
|
61,881 |
|
|
63,765 |
|
Short term
borrowings (including short term borrowings of the
consolidated |
|
|
|
|
|
|
|
VIEs without
recourse to iKang Healthcare Group, Inc. of $53,364 |
|
|
|
|
|
|
|
and $30,769
as of March 31, 2016 and June 30, 2016, respectively) |
|
|
53,364 |
|
|
30,769 |
|
|
|
|
|
|
|
|
|
Total current
liabilities |
|
$ |
199,000 |
|
$ |
179,730 |
|
|
|
|
|
|
|
|
|
IKANG HEALTHCARE GROUP,
INC. |
|
CONDENSED CONSOLIDATED BALANCE SHEETS -
continued |
|
(In thousands of US dollars, except share data and per
share data) |
|
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
As of |
|
As of |
|
|
|
March 31, |
|
June 30, |
|
|
|
2016 |
|
2016 |
|
|
|
|
|
|
|
|
|
|
Long-term borrowings
(including long term borrowings of the consolidated |
|
|
|
|
|
|
|
VIEs and VIEs’
subsidiaries without recourse to iKang Healthcare Group, Inc. |
|
|
|
|
|
|
|
of $229,467 and $226,170
as of March 31, 2016 and June 30, 2016, respectively) |
|
229,467 |
|
|
226,170 |
|
|
Deferred tax
liabilities-non-current (including deferred tax liabilities |
|
|
|
|
|
|
|
non-current
of the consolidated VIEs without recourse to iKang |
|
|
|
|
|
|
|
Healthcare
Group, Inc. of $9,422 and $8,806 as of March 31, 2016 and |
|
|
|
|
|
|
|
June 30,
2015, respectively) |
|
9,772 |
|
|
9,091 |
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES |
$ |
438,239 |
|
$ |
414,991 |
|
|
|
|
|
|
|
|
|
|
Equity: |
|
|
|
|
|
|
|
Total iKang
Healthcare Group, Inc. shareholders' equity |
|
342,826 |
|
|
330,666 |
|
|
Non-controlling interests |
|
22,576 |
|
|
22,282 |
|
|
|
|
|
|
|
|
|
|
TOTAL EQUITY |
|
365,402 |
|
|
352,948 |
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND
EQUITY |
$ |
803,641 |
|
$ |
767,939 |
|
|
|
|
|
|
|
|
|
|
IKANG HEALTHCARE GROUP, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(In thousands of US dollars, except share data and per
share data) |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
Three-month periods |
|
|
|
ended June 30, |
|
|
|
|
2015 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
Net revenues |
|
$ |
86,297 |
|
$ |
101,238 |
|
Cost of revenues |
|
|
44,152 |
|
|
56,505 |
|
|
|
|
|
|
|
|
|
Gross profit |
|
$ |
42,145 |
|
$ |
44,733 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Selling and
marketing expenses |
|
$ |
14,031 |
|
$ |
18,301 |
|
General and
administrative expenses |
|
|
12,967 |
|
|
18,702 |
|
Research and
development expenses |
|
|
717 |
|
|
884 |
|
|
|
|
|
|
|
|
|
Total operating
expenses |
|
$ |
27,715 |
|
$ |
37,887 |
|
|
|
|
|
|
|
|
|
Income from
operations |
|
$ |
14,430 |
|
$ |
6,846 |
|
Interest expenses |
|
|
(396 |
) |
|
(3,281 |
) |
Interest income |
|
|
186 |
|
|
376 |
|
|
|
|
|
|
|
|
|
Income before income tax
expenses and gain from |
|
|
|
|
|
|
|
equity
method investments |
|
$ |
14,220 |
|
$ |
3,941 |
|
Income tax expenses |
|
|
3,783 |
|
|
985 |
|
Loss from equity method
investments |
|
|
- |
|
|
(1,037 |
) |
|
|
|
|
|
|
|
|
Net income |
|
$ |
10,437 |
|
$ |
1,919 |
|
Less: Net loss
attributable to non-controlling interests |
|
|
(225 |
) |
|
(147 |
) |
|
|
|
|
|
|
|
|
Net income attributable to
iKang Healthcare Group, Inc. |
|
$ |
10,662 |
|
$ |
2,066 |
|
|
|
|
|
|
|
|
|
Net income attributable to
common shareholders |
|
|
|
|
|
|
|
of iKang Healthcare Group,
Inc. |
|
$ |
10,662 |
|
$ |
2,066 |
|
|
|
|
|
|
|
|
|
Net income per share
attributable to common shareholders |
|
|
|
|
|
|
|
of iKang
Healthcare Group, Inc. |
|
|
|
|
|
|
|
Basic |
|
$ |
0.31 |
|
$ |
0.06 |
|
Diluted |
|
$ |
0.30 |
|
$ |
0.06 |
|
|
|
|
|
|
|
|
|
Net income per ADS (one
common share equals to two ADSs) |
|
|
|
|
|
|
|
Basic |
|
$ |
0.16 |
|
$ |
0.03 |
|
Diluted |
|
$ |
0.15 |
|
$ |
0.03 |
|
|
|
|
|
|
|
|
|
Weighted average shares
used in calculating net income |
|
|
|
|
|
|
|
per common
share |
|
|
|
|
|
|
|
Basic |
|
|
34,361,539 |
|
|
33,955,067 |
|
Diluted |
|
|
35,290,545 |
|
|
34,654,762 |
|
|
|
|
|
|
|
|
|
IKANG HEALTHCARE GROUP, INC. |
RECONCILIATION OF GAAP AND NON-GAAP
RESULTS |
(In thousands of US dollars, except share data and per
share data) |
(Unaudited) |
|
|
|
|
|
|
Three-month periods |
|
|
|
ended June 30, |
|
|
|
|
2015 |
|
|
2016 |
|
|
|
|
|
|
|
|
|
Income from
operations |
|
$ |
14,430 |
|
$ |
6,846 |
|
Add: |
|
|
|
|
|
|
|
Share-based
compensation expenses |
|
|
492 |
|
|
484 |
|
|
|
|
|
|
|
|
|
Non-GAAP operating
income |
|
$ |
14,922 |
|
$ |
7,330 |
|
|
|
|
|
|
|
|
|
Net income attributable to
iKang Healthcare Group, Inc. |
|
$ |
10,662 |
|
$ |
2,066 |
|
Add: |
|
|
|
|
|
|
|
Share-based
compensation expenses |
|
|
492 |
|
|
484 |
|
|
|
|
|
|
|
|
|
Non-GAAP net income |
|
$ |
11,154 |
|
$ |
2,550 |
|
|
|
|
|
|
|
|
|
Income from
operations |
|
$ |
14,430 |
|
$ |
6,846 |
|
Add: |
|
|
|
|
|
|
|
Depreciation
and amortization |
|
|
6,776 |
|
|
8,647 |
|
Share-based
compensation expenses |
|
|
492 |
|
|
484 |
|
|
|
|
|
|
|
|
|
Non-GAAP EBITDA |
|
$ |
21,698 |
|
$ |
15,977 |
|
|
|
|
|
|
|
|
|
Non-GAAP net income
attributable to common shareholders |
|
|
|
|
|
|
|
of iKang
Healthcare Group, Inc. |
|
$ |
11,154 |
|
$ |
2,550 |
|
|
|
|
|
|
|
|
|
Non-GAAP net income per
share attributable to common shareholders |
|
|
|
|
|
|
|
of iKang
Healthcare Group, Inc. |
|
|
|
|
|
|
|
Basic |
|
$ |
0.33 |
|
$ |
0.08 |
|
Diluted |
|
$ |
0.32 |
|
$ |
0.07 |
|
|
|
|
|
|
|
|
|
Non-GAAP net income per
ADS (one common share equals to two ADSs) |
|
|
|
|
|
|
|
Basic |
|
$ |
0.16 |
|
$ |
0.04 |
|
Diluted |
|
$ |
0.16 |
|
$ |
0.04 |
|
|
|
|
|
|
|
|
|
IR Contact:
iKang Healthcare Group, Inc.
Christy Xie
Director of Investor Relations
Tel: +86 10 5320 8599
Email: ir@ikang.com
Website: www.ikanggroup.com
FleishmanHillard
Email: ikang@fleishman.com
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Historical Stock Chart
From Aug 2024 to Sep 2024
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Historical Stock Chart
From Sep 2023 to Sep 2024